• Publications
  • Influence
Buprenorphine: considerations for pain management.
New effective analgesics are needed for the treatment of pain. Buprenorphine, a partial mu-opioid agonist which has been in clinical use for over 25 years, has been found to be amenable to newExpand
  • 221
  • 16
  • PDF
A controlled trial of buprenorphine treatment for opioid dependence.
OBJECTIVE To assess the efficacy of buprenorphine for short-term maintenance/detoxification. DESIGN A randomized, double-blind, parallel group study comparing buprenorphine, 8 mg/d, methadone, 60Expand
  • 519
  • 13
A clinical trial of buprenorphine: Comparison with methadone in the detoxification of heroin addicts
The efficacy of buprenorphine and methadone was compared in the outpatient detoxification of heroin addicts. Forty‐five patients were randomized to receive either sublingual buprenorphine or oralExpand
  • 262
  • 10
Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome.
This study was designed to compare the neonatal abstinence syndrome (NAS) in neonates of methadone and buprenorphine maintained pregnant opioid-dependent women and to provide preliminary safety andExpand
  • 263
  • 10
  • PDF
Concurrent validation of the Clinical Opiate Withdrawal Scale (COWS) and single-item indices against the Clinical Institute Narcotic Assessment (CINA) opioid withdrawal instrument.
INTRODUCTION The Clinical Opiate Withdrawal Scale (COWS) is an 11-item clinician-administered scale assessing opioid withdrawal. Though commonly used in clinical practice, it has not beenExpand
  • 91
  • 8
  • PDF
Clonidine in morphine withdrawal. Differential effects on signs and symptoms.
Reports of an antiwithdrawal effect for clonidine hydrochloride in acute opioid withdrawal are inconsonant with experimental findings that other nonopioids are ineffective. In the presentExpand
  • 159
  • 7
Buprenorphine: dose-related blockade of opioid challenge effects in opioid dependent humans.
This study assessed the blockade of hydromorphone challenge effects (cumulative s.c. doses of 0, 6 and 18 mg) during chronic buprenorphine treatment of opioid dependent subjects. Buprenorphine wasExpand
  • 211
  • 6
Buprenorphine: how to use it right.
The unique pharmacology of buprenorphine at the mu-opioid receptor (i.e. high affinity, low intrinsic activity and slow dissociation) results in buprenorphine having: (1) a good safety profile, (2)Expand
  • 198
  • 6
Sublingual versus subcutaneous buprenorphine in opiate abusers
To compare the pharmacologic profiles of sublingually and subcutaneously administered buprenorphine, 10 healthy male subjects with histories of opiate abuse were given sublingually administeredExpand
  • 97
  • 6
Use of buprenorphine in pregnancy: patient management and effects on the neonate.
It is estimated that 55-94% of infants born to opioid-dependent mothers in US will show signs of opioid withdrawal. Buprenorphine has been reported to produce little or no autonomic signs or symptomsExpand
  • 184
  • 5
  • PDF